Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Must not have
Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study
Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to week 16 (inclusive)
Summary
"This trial will compare a new drug to a placebo to see how it affects calorie intake, energy metabolism, and appetite. It will last up to 6 months and participants may have up to 20
Who is the study for?
This trial is for individuals with obesity, defined as having a BMI greater than 30 kg/m2. Participants should have tried at least one diet to lose weight without success. Specific details on who can't join are not provided.
What is being tested?
The study is testing LY3437943 against a placebo to see its effects on how many calories participants eat, their energy use, and appetite levels. It involves up to 20 visits over a maximum of six months.
What are the potential side effects?
Potential side effects of LY3437943 aren't detailed here, but common drug-related risks may include digestive issues, changes in appetite or metabolism, and possible reactions at the injection site if applicable.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have lost or gained more than 11 pounds in the last 3 months.
Select...
I have a history of thyroid cancer or MEN2 in my family or myself.
Select...
I have hepatitis.
Select...
I have a history of pancreatitis.
Select...
I have diabetes and have experienced severe complications.
Select...
I haven't had a blood transfusion or severe blood loss in the last 3 months and don't have any blood disorders.
Select...
I have had or am planning to have surgery or device-based therapy for obesity.
Select...
I have not had a heart attack, stroke, heart surgery, or been hospitalized for heart issues in the last 3 months.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to week 16 (inclusive)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to week 16 (inclusive)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change from Baseline in 24-hour Energy Expenditure (EE)
Change from Baseline in Sleep Metabolic Rate (SMR)
Side effects data
From 2022 Phase 2 trial • 281 Patients • NCT0486778520%
Decreased appetite
20%
Nausea
15%
Diarrhoea
11%
Constipation
11%
Vomiting
11%
Upper respiratory tract infection
11%
Urinary tract infection
7%
Fatigue
7%
Dyspepsia
4%
Anaemia
4%
Covid-19
4%
Lipase increased
4%
Dizziness
4%
Weight decreased
2%
Cellulitis
2%
Diabetic ketoacidosis
2%
Abdominal pain
2%
Eructation
2%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3437943 (2 mg)
8 mg LY3437943 (2 mg)
Placebo
1.5 Milligram (mg) Dulaglutide
0.5 mg LY3437943
4 mg LY3437943 (2 mg)
4 mg LY3437943 (4 mg)
8 mg LY3437943 (4 mg)
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3437943Experimental Treatment1 Intervention
LY3437943 administered subcutaneously (SC)
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered SC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3437943
2022
Completed Phase 2
~1090
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,670 Previous Clinical Trials
3,228,695 Total Patients Enrolled
69 Trials studying Obesity
55,298 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,385 Previous Clinical Trials
426,317 Total Patients Enrolled
51 Trials studying Obesity
34,840 Patients Enrolled for Obesity
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger